T2DM

Integrity Applications Issues Shareholder Update Letter

Retrieved on: 
Monday, December 20, 2021
Doctor of Philosophy, Coronavirus Scientific Advisory Board (Turkey), News, GLOBE, Integrated Applications Promotion, Glycated hemoglobin, Leadership, FDA, Time, Electronics, Insurance, Algorithm, Physician, Technology, Diabetes, Pain, Annual report, Emergency, Type 2, Letter, Risk, Software, NASDAQ, Prediabetes, General manager, MD, Principal investigator, Private Securities Litigation Reform Act, DE, Industry, U.S. Securities and Exchange Commission, Machine learning, Smartphone, Company, Medtronic, Ear, SEC, T2DM, Integrity, Type 2 diabetes, Patient, Management, Medical device, Security (finance), Video game console, Dexcom, Nasdaq, Engineering

Wilmington, DE and Or Yehuda, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. ( www.integrity-app.com ) (NASDAQ: IGAP), innovator of GlucoTrack , a non-invasive device for measuring glucose levels in people with Type II diabetes and prediabetes announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a message and year-to-date shareholder update letter.

Key Points: 
  • Wilmington, DE and Or Yehuda, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. ( www.integrity-app.com ) (NASDAQ: IGAP), innovator of GlucoTrack , a non-invasive device for measuring glucose levels in people with Type II diabetes and prediabetes announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a message and year-to-date shareholder update letter.
  • We believe this listing will enable the company and its shareholders greater access to liquidity, increased corporate visibility and a broader shareholder base.
  • Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel.
  • Readers are cautioned that certain important factors may affect Integrity Applications actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release.

Integrity Applications Issues Shareholder Update Letter

Retrieved on: 
Monday, December 20, 2021
Doctor of Philosophy, Coronavirus Scientific Advisory Board (Turkey), News, GLOBE, Integrated Applications Promotion, Glycated hemoglobin, Leadership, FDA, Time, Electronics, Insurance, Algorithm, Physician, Technology, Diabetes, Pain, Annual report, Emergency, Type 2, Letter, Risk, Software, NASDAQ, Prediabetes, General manager, MD, Principal investigator, Private Securities Litigation Reform Act, DE, Industry, U.S. Securities and Exchange Commission, Machine learning, Smartphone, Company, Medtronic, Ear, SEC, T2DM, Integrity, Type 2 diabetes, Patient, Management, Medical device, Security (finance), Video game console, Dexcom, Nasdaq, Engineering

Wilmington, DE and Or Yehuda, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. ( www.integrity-app.com ) (NASDAQ: IGAP), innovator of GlucoTrack , a non-invasive device for measuring glucose levels in people with Type II diabetes and prediabetes announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a message and year-to-date shareholder update letter.

Key Points: 
  • Wilmington, DE and Or Yehuda, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. ( www.integrity-app.com ) (NASDAQ: IGAP), innovator of GlucoTrack , a non-invasive device for measuring glucose levels in people with Type II diabetes and prediabetes announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a message and year-to-date shareholder update letter.
  • We believe this listing will enable the company and its shareholders greater access to liquidity, increased corporate visibility and a broader shareholder base.
  • Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel.
  • Readers are cautioned that certain important factors may affect Integrity Applications actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release.

2021 Diabetes Device Intelligence Center Report with Growth Trends up to 2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Health, Diabetes, T2DM, Population, Blood, Urbanization, Roy Taylor (scientist), Habit, CAGR, Globe, Medtronic, Abbott, Patient, R, Obesity, Prevalence, CGM, Pharmaceutical industry, Soft drink, Diabetes

The Diabetes Device market is expected to grow because of the rising diabetic population levels and increasing diabetes expenditure in established and emerging countries.

Key Points: 
  • The Diabetes Device market is expected to grow because of the rising diabetic population levels and increasing diabetes expenditure in established and emerging countries.
  • The Type 1 diabetes population completely depend on insulin therapy, and therefore, they constantly need to monitor their blood glucose.
  • Global Rise in Diabetic Population Levels:
    There has been a tremendous increase in the global diabetic population levels over the past decade.
  • It is estimated that out of the total 415 million people suffering from diabetes worldwide, 46% of this demographic is those with undiagnosed diabetes.

Global Diabetes Drug Intelligence Center Database 2021 - Featuring Astellas, AstraZeneca and Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 8, 2021
Health, General Health, Habit, Genetic causes of type 2 diabetes, Type 2 diabetes, Population, Novo Nordisk, Prevalence, Type 1 diabetes, Sanofi, USD, Diabetes, Biocon, CAGR, Eli Lilly, T2DM, Urbanization, Obesity, Pharmaceutical industry

However, due to high competitions in the local markets, consumer penetration for their products is being worked on continuously.

Key Points: 
  • However, due to high competitions in the local markets, consumer penetration for their products is being worked on continuously.
  • Global Rise in Diabetic Population:
    There has been a tremendous increase in the diabetic population levels globally, over the last decade.
  • It is estimated that out of the total 415 million people suffering from diabetes worldwide, 46% of this demographic is those with undiagnosed diabetes.
  • Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of Type-1 and Type-2 diabetes mellitus.

2021 Diabetes Care Intelligence Center Database - ResearchAndMarkets.com

Retrieved on: 
Monday, December 6, 2021
Health, Diabetes, Patient, CGMS-A, T2DM, Prevalence, Diabetes, Urbanization, Obesity, Roy Taylor (scientist), Habit, Population, Globe, Pharmaceutical industry

The global diabetes care market is expected to grow because of the growing diabetes population levels and increasing diabetes expenditure in established, as well as pharm emerging countries.

Key Points: 
  • The global diabetes care market is expected to grow because of the growing diabetes population levels and increasing diabetes expenditure in established, as well as pharm emerging countries.
  • Several reports and surveys documented a drastic increase in the diabetic population levels, based on the changing lifestyles and habits.
  • Owing to these factors the prevalence of Type 2 Diabetes mellitus (T2DM) has increased significantly.
  • It is estimated that out of the total 415 million people suffering from diabetes worldwide, 46% of this demographic is those with undiagnosed diabetes.

HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021

Retrieved on: 
Thursday, October 28, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fibrosis, Program, UDCA, Astrophysics Strategic Mission Concept Studies, Orphan drug, Weight loss, Central nervous system disease, 2021 Essex County Council election, AASLD, Primary sclerosing cholangitis, Fatty liver disease, Ursodeoxycholic acid, PBC, US, Association, CNS, NAFLD, Fast Track, T2DM, Patient, Liver injury, Roy Taylor (scientist), ALT, Cholestasis, Liver disease, American Association for the Study of Liver Diseases, HighTide, Chronic liver disease, PSC, American Association, Therapy, NASH, Diabetes, Doctor of Philosophy, Berberine, Primary biliary cholangitis, Pharmaceutical industry, Medical imaging, Dietary supplement, HTD1801, HighTide Therapeutics, HTD1801, HIGHTIDE THERAPEUTICS

HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).
  • The data will be presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2021, being held virtually November 12-15, 2021.
  • We are excited to present new HTD1801 clinical data in both PSC and NASH, said Liping Liu, PhD, Founder and Chief Executive Officer of HighTide.
  • HTD1801 has received Fast Track designation from the US FDA for both PSC and NASH, as well as Orphan Drug designation for PSC.

Can low liver fat be bad for your heart? AMRA Medical helps explore this question with MRI

Retrieved on: 
Tuesday, September 28, 2021
Biobank, Mayo Clinic Proceedings, Type 2, MRI, Liver disease, Health, T2DM, Database, Multimedia, Precision medicine, University Hospitals Cleveland Medical Center, Adipose tissue, Non-alcoholic fatty liver disease, NAFLD, VAT, University of Texas Southwestern Medical Center, Cardiovascular disease, Phenotype, Reading, Fatty liver disease, Disease, CVD, Risk, Type 2 diabetes, Lists of diseases, Research, CHD, Obesity, UK Biobank, Safety, Institute of Liver and Biliary Sciences, Moyamoya disease, Association, Dietary supplement, Medical imaging

In the presence of visceral obesity, low liver fat was associated with coronary heart disease (CHD).

Key Points: 
  • In the presence of visceral obesity, low liver fat was associated with coronary heart disease (CHD).
  • Low liver fat in a patient with visceral obesity may indicate a dysfunction in the liver's capacity to accumulate fat.
  • AMRA Medical is a digital health company at the forefront of medical imaging and precision medicine.
  • AMRA offers medical device and medical research services to support transformative care and vital decision-making, from clinical research to clinical care.

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

Retrieved on: 
Sunday, September 26, 2021
DREAM, Neurodegeneration, Type 2, NDA, Stock exchange, T2DM, Conference, Diabetes, Patient, BMJ, Association, Glycated hemoglobin, Metformin, American Diabetes Association, NASH, CEO, Observational study, National Medical Products Administration, Company, Prevalence, SEED, Disease, Trial of the century, Hong Kong Stock Exchange, Glucokinase, Intelligence, Research, Big data, Insulin, 52 Weeks Make A Year, Safety, Insulin resistance, Prediabetes, Kaplan–Meier estimator, Type 2 diabetes, LSE Alternative Investment Conference, Department, Pharmaceutical industry

The SEED study is a Phase III registered clinical study of dorzagliatin monotherapy in drug-naive Type 2 diabetes patients to observe its long-term efficacy and safety.

Key Points: 
  • The SEED study is a Phase III registered clinical study of dorzagliatin monotherapy in drug-naive Type 2 diabetes patients to observe its long-term efficacy and safety.
  • The researchers comprehensively evaluated the subjects and set their individual HbA1c control goals, and the results of the research showed that the subjects had a 52-week glucose remission rate of 65.2% (95% CI, 53.4%, 77.0%) [1] during the research period.
  • The DREAM study explores the possibility of oral dosing in diabetes remission and is of great significance in expanding the treatment options for Type 2 diabetes."
  • Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive, degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes.

HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients

Retrieved on: 
Tuesday, September 21, 2021
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ursodeoxycholic acid, Therapy, HighTide, Prevalence, Weight loss, Type 2 diabetes, Fatty liver disease, Liver disease, Berberine, PSC, Inflammation, T2DM, Liver injury, Biliary reflux, Diabetes, Fast Track, Patient, MD, NAFLD, Nausea, Liver cancer, Glycated hemoglobin, NASH, CEO, Magnetic resonance imaging, Degenerative disease, Nature Communications, Disease, Hepatitis, CTCAE, Liver, Lists of diseases, BID, Safety, Fibrosis, Cirrhosis, Orphan drug, US, Diarrhea, Pharmaceutical industry, Medical imaging, NASH, HTD1801, HighTide Therapeutics, NASH, HTD1801, HIGHTIDE THERAPEUTICS

The totality of the data support our expectation that HTD1801 could benefit a significant number of patients with NASH and diabetes, said Liping Liu, CEO of HighTide.

Key Points: 
  • The totality of the data support our expectation that HTD1801 could benefit a significant number of patients with NASH and diabetes, said Liping Liu, CEO of HighTide.
  • NASH is often a liver manifestation of a systemic metabolic disorder, said Stephen Harrison, MD, medical director of Pinnacle Clinical Research and lead author.
  • This trial in patients with presumed NASH and T2DM demonstrated HTD1801s potential to treat NASH while also addressing the underlying metabolic driver of the disease.
  • The study results show that HTD1801 is relatively well tolerated and merits further development as a treatment for NASH with diabetes.

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Retrieved on: 
Wednesday, September 15, 2021
Insulin, Metformin, NDA, National Medical Products Administration, CEO, Efficiency, Sinopharm Group, Marketing, Diabetes, Ecosystem, Patient, Shanghai Stock Exchange, Company, Type 2, Medicine, GKA, Bayer, T2DM, Homeostasis, Disease, New Drug Application, HK, T2D, Glucokinase, City, Stock exchange, NMPA, News, Type 2 diabetes, Partnership, Hong Kong Stock Exchange, Pharmaceutical industry

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.